Having trouble accessing articles? Reset your cache.

Novartis discloses CRL for Neulasta biosimilar

In 2Q16 results announced Tuesday, Novartis AG (NYSE:NVS; SIX:NOVN) said its Sandoz unit received a complete response letter from FDA for LA-EP2006, its proposed biosimilar of neutropenia drug Neulasta

Read the full 299 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE